Tomoko Iwata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tomoko Iwata has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Chu-Xia Deng
Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, China
3 shared publications Francesca Pellicano
Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, Beatson Laboratories for Cancer Research, Glasgow, UK
3 shared publications- Hing Y. Leung
CRUK Beatson Institute
3 shared publications - Imran Ahmad
Florida International University
3 shared publications - Owen James Sansom
School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
3 shared publications Clair A. Francomano
Medical Genetics Branch, National Human Genome Research Institute and Genetics of Development and Disease Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, 10/3D51, 10 Center Drive, Bethesda, MD, 20892, USA
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 249
Novel adenoma-immune phenotypes are associated with risk of metachronous polyps and colorectal cancer in a bowel screening cohort
- 4 November 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 249
Open AccessNovel adenoma-immune phenotypes are associated with risk of metachronous polyps and colorectal cancer in a bowel screening cohort
- Open Access
- 4 September 2026
- Published by University of the Highlands and Islands in Journal of Perspectives in Applied Academic Practice
- Vol. 14 (3)
Mentoring scheme as a driver of equality, diversity and inclusion in health professions education and research
Mentoring is one of the important modalities that are known to enhance professional development of staff, including those who engage in teaching and learning of Health Professions in Higher Education as well as research of patients-focused subjects. However, while multiple mentoring schemes are available at University level, the impact they bring to the local community of staff is often unclear. With an aim to identify the current status of mentoring within the School of Medicine, Dentistry and Nursing, University of Glasgow, the Athena Swan-led Aspiration and Development Working Group has conducted a reflective study. We analysed benefits of the existing mentoring schemes, as well as challenges met by staff in the early stages of career in the Learning, Teaching and Scholarship and the Research and Teaching tracks. Reflection was also made on the equality, diversity and inclusion of Postgraduate Research students and LGBTQ+ members of the community. We have found that there was a limited uptake despite benefits, and that there were multiple causes for this, which was beyond a lack of time. This has led to a proposal of a new mentoring scheme that focuses on local needs and the process that centres more favourably to the prospective mentees, by reducing the hurdle for participation and providing more flexibility in the format, frequency and content, with an integrated monitoring platform of the scheme, which supports sustainability. We find that, for provision of a meaningful mentoring, careful design and implementation based on the EDI ethos is essential.
- 4 September 2026
- Published by University of the Highlands and Islands in Journal of Perspectives in Applied Academic Practice
- Vol. 14 (3)
Open AccessMentoring scheme as a driver of equality, diversity and inclusion in health professions education and research
Mentoring is one of the important modalities that are known to enhance professional development of staff, including those who engage in teaching and learning of Health Professions in Higher Education as well as research of patients-focused subjects. However, while multiple mentoring schemes are available at University level, the impact they bring to the local community of staff is often unclear. With an aim to identify the current status of mentoring within the School of Medicine, Dentistry and Nursing, University of Glasgow, the Athena Swan-led Aspiration and Development Working Group has conducted a reflective study. We analysed benefits of the existing mentoring schemes, as well as challenges met by staff in the early stages of career in the Learning, Teaching and Scholarship and the Research and Teaching tracks. Reflection was also made on the equality, diversity and inclusion of Postgraduate Research students and LGBTQ+ members of the community. We have found that there was a limited uptake despite benefits, and that there were multiple causes for this, which was beyond a lack of time. This has led to a proposal of a new mentoring scheme that focuses on local needs and the process that centres more favourably to the prospective mentees, by reducing the hurdle for participation and providing more flexibility in the format, frequency and content, with an integrated monitoring platform of the scheme, which supports sustainability. We find that, for provision of a meaningful mentoring, careful design and implementation based on the EDI ethos is essential.
- Open Access
- 1 September 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-4
Why early pathology input matters in biologically rich cancer trials
Pathology is central to many biologically driven cancer clinical trials. Biomarker-led and translational studies depend on robust tissue pathways, cellular and molecular assays, pathology-derived endpoints, and clinically meaningful interpretation of discovery science. Where trials depend on tumour material, biomarker-defined eligibility or mechanism-focused endpoints, pathology expertise should be embedded early, before protocols, budgets, and assays are fixed. Early pathology input strengthens feasibility, specimen governance, assay selection, quality assurance, and the long-term value of collected samples. In the UK, the Clinical Trials Pathology Advisory Group, now within the new Pathological Society of Great Britain and Ireland Clinical Trials Pathology subcommittee, provides a practical route for pre-submission specialist review. This Perspective argues that pathology is core infrastructure for biologically rich trials, linking discovery science to clinical translation.
- 1 September 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-4
Open AccessWhy early pathology input matters in biologically rich cancer trials
Pathology is central to many biologically driven cancer clinical trials. Biomarker-led and translational studies depend on robust tissue pathways, cellular and molecular assays, pathology-derived endpoints, and clinically meaningful interpretation of discovery science. Where trials depend on tumour material, biomarker-defined eligibility or mechanism-focused endpoints, pathology expertise should be embedded early, before protocols, budgets, and assays are fixed. Early pathology input strengthens feasibility, specimen governance, assay selection, quality assurance, and the long-term value of collected samples. In the UK, the Clinical Trials Pathology Advisory Group, now within the new Pathological Society of Great Britain and Ireland Clinical Trials Pathology subcommittee, provides a practical route for pre-submission specialist review. This Perspective argues that pathology is core infrastructure for biologically rich trials, linking discovery science to clinical translation.
- Open Access
- 11 February 2026
- Published by Center for Open Science in EdArXiv
Mentoring scheme as a driver of equality, diversity and inclusion in health professions education and research
Mentoring is one of the important modalities that are known to enhance professional development of staff, including those who engage in teaching and learning of Health Professions in Higher Education as well as research of patients-focused subjects. However, while multiple mentoring schemes are available at University level, the impact they bring to the local community of staff is often unclear. With an aim to identify the current status of mentoring within School of Medicine, Dentistry and Nursing, University of Glasgow, the Athena Swan-led Aspiration and Development Working Group has conducted a reflective study. We analysed benefits of the existing mentoring schemes, as well as challenges met by staff in the early stages of career in the Learning, Teaching and Scholarship and the Research and Teaching tracks. Reflection was also made on the equality, diversity and inclusion of Postgraduate Research students and LGBTQ+ members of the community. We have found that there was a limited uptake despite benefits, and that there were multiple causes for this, which was beyond a lack of time. This has led to a proposal of a new mentoring scheme that focuses on local needs and the process that centres more favourably to the prospective mentees, with an integrated monitoring platform of the scheme, which supports sustainability. We find that, for provision of a meaningful mentoring, careful design and implementation based on the EDI ethos is essential.
- 11 February 2026
- Published by Center for Open Science in EdArXiv
Open AccessMentoring scheme as a driver of equality, diversity and inclusion in health professions education and research
Mentoring is one of the important modalities that are known to enhance professional development of staff, including those who engage in teaching and learning of Health Professions in Higher Education as well as research of patients-focused subjects. However, while multiple mentoring schemes are available at University level, the impact they bring to the local community of staff is often unclear. With an aim to identify the current status of mentoring within School of Medicine, Dentistry and Nursing, University of Glasgow, the Athena Swan-led Aspiration and Development Working Group has conducted a reflective study. We analysed benefits of the existing mentoring schemes, as well as challenges met by staff in the early stages of career in the Learning, Teaching and Scholarship and the Research and Teaching tracks. Reflection was also made on the equality, diversity and inclusion of Postgraduate Research students and LGBTQ+ members of the community. We have found that there was a limited uptake despite benefits, and that there were multiple causes for this, which was beyond a lack of time. This has led to a proposal of a new mentoring scheme that focuses on local needs and the process that centres more favourably to the prospective mentees, with an integrated monitoring platform of the scheme, which supports sustainability. We find that, for provision of a meaningful mentoring, careful design and implementation based on the EDI ethos is essential.
- 1 January 2024
- Published by Springer Nature
- p. 317-341
The Emerging Landscape of Mouse Bladder Cancer Models
- 1 January 2024
- Published by Springer Nature
- p. 317-341
The Emerging Landscape of Mouse Bladder Cancer Models
- Open Access
- 8 May 2023
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 25 (7) , 970-977
Empagliflozin in Heart Failure with Preserved Ejection Fraction with and without Atrial Fibrillation
Aims: Atrial fibrillation/flutter (AF) is common in heart failure (HF) with preserved left ventricular ejection fraction (LVEF) and associated with worse outcomes. Empagliflozin reduces cardiovascular death or HF hospitalizations and slows estimated glomerular filtration rate (eGFR) decline in patients with HF and LVEF >40%. We aimed to assess the efficacy and safety of empagliflozin in improving outcomes in patients with HF and LVEF >40% with and without AF. Methods and results: In this pre-defined secondary analysis of EMPEROR-Preserved, we compared the effects of empagliflozin versus placebo on the primary and secondary endpoints and safety outcomes, stratified by baseline AF, defined as AF reported in any electrocardiogram before empagliflozin initiation or in medical history. Among 5988 patients randomized, 3135 (52%) had baseline AF; these patients were older, with worse functional class, more previous HF hospitalizations and higher natriuretic peptides compared to those without AF (all p < 0.001). After a median of 26 months, empagliflozin reduced cardiovascular death or HF hospitalization compared to placebo to a similar extent in patients with and without AF (hazard ratio [HR] 0.78 [95% confidence interval 0.66–0.93] vs. 0.78 [0.64–0.95], interaction p = 0.96). Empagliflozin also reduced total HF hospitalizations (HR 0.73 [0.57–0.94] vs. 0.72 [0.54–0.95], interaction p = 0.94) and annual eGFR decline (difference = 1.368 vs. 1.372 ml/min/1.73 m2/year, interaction p = 0.99) consistently in patients with and without AF. There was no increase in serious adverse events with empagliflozin versus placebo in patients with and without AF. Conclusions: In patients with HF and ejection fraction >40%, empagliflozin reduced the risk of serious HF events and slowed the eGFR decline regardless of baseline AF.
- 8 May 2023
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 25 (7) , 970-977
Open AccessEmpagliflozin in Heart Failure with Preserved Ejection Fraction with and without Atrial Fibrillation
Aims: Atrial fibrillation/flutter (AF) is common in heart failure (HF) with preserved left ventricular ejection fraction (LVEF) and associated with worse outcomes. Empagliflozin reduces cardiovascular death or HF hospitalizations and slows estimated glomerular filtration rate (eGFR) decline in patients with HF and LVEF >40%. We aimed to assess the efficacy and safety of empagliflozin in improving outcomes in patients with HF and LVEF >40% with and without AF. Methods and results: In this pre-defined secondary analysis of EMPEROR-Preserved, we compared the effects of empagliflozin versus placebo on the primary and secondary endpoints and safety outcomes, stratified by baseline AF, defined as AF reported in any electrocardiogram before empagliflozin initiation or in medical history. Among 5988 patients randomized, 3135 (52%) had baseline AF; these patients were older, with worse functional class, more previous HF hospitalizations and higher natriuretic peptides compared to those without AF (all p < 0.001). After a median of 26 months, empagliflozin reduced cardiovascular death or HF hospitalization compared to placebo to a similar extent in patients with and without AF (hazard ratio [HR] 0.78 [95% confidence interval 0.66–0.93] vs. 0.78 [0.64–0.95], interaction p = 0.96). Empagliflozin also reduced total HF hospitalizations (HR 0.73 [0.57–0.94] vs. 0.72 [0.54–0.95], interaction p = 0.94) and annual eGFR decline (difference = 1.368 vs. 1.372 ml/min/1.73 m2/year, interaction p = 0.99) consistently in patients with and without AF. There was no increase in serious adverse events with empagliflozin versus placebo in patients with and without AF. Conclusions: In patients with HF and ejection fraction >40%, empagliflozin reduced the risk of serious HF events and slowed the eGFR decline regardless of baseline AF.
- Open Access
- 1 June 2022
- Published by SAGE Publications in Bladder Cancer
- Vol. 8 (3) , 277-290
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer
BACKGROUND: CXCR2 is a chemokine receptor expressed in myeloid cells, including neutrophils and macrophages. Pharmacological inhibition of CXCR2 has been shown to sensitize tumours to immune checkpoint inhibitor immunotherapies in some cancer types. OBJECTIVE: To investigate the effects of CXCR2 loss in regulation of tumour-infiltrating myeloid cells and their relationship to lymphocytes during bladder tumorigenesis. METHODS: Urothelial pathogenesis and immune contexture was investigated in an OH-BBN model of invasive bladder cancer with Cxcr2 deleted in myeloid cells ( LysMCre Cxcr2 flox/flox ). CXCR2 gene alterations and expression in human muscle invasive bladder cancer were analysed in The Cancer Genome Atlas. RESULTS: Urothelial tumour pathogenesis was significantly increased upon Cxcr2 deletion compared to wildtype mice. This was associated with a suppression of myeloid cell infiltration in Cxcr2-deleted bladders shortly after the carcinogen induction. Interestingly, following a transient increase of macrophages at the outset of tumour formation, an increase in T cell infiltration was observed in Cxcr2-deleted tumours. The increased tumour burden in the Cxcr2-deleted bladder was largely independent of T cells and the status of immune suppression. The Cxcr2-deleted mouse model reflected the low CXCR2 mRNA range in human bladder cancer, which showed poor overall survival. CONCLUSIONS: In contrast to previous reports of increased CXCR2 signalling associated with disease progression and poor prognosis, CXCR2 was protective against bladder cancer during tumour initiation. This is likely due to a suppression of acute inflammation. The strategy for sensitizing checkpoint immunotherapy by CXCR2 inhibition in bladder cancer may benefit from an examination of immune suppressive status.
- 1 June 2022
- Published by SAGE Publications in Bladder Cancer
- Vol. 8 (3) , 277-290
Open AccessLoss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer
BACKGROUND: CXCR2 is a chemokine receptor expressed in myeloid cells, including neutrophils and macrophages. Pharmacological inhibition of CXCR2 has been shown to sensitize tumours to immune checkpoint inhibitor immunotherapies in some cancer types. OBJECTIVE: To investigate the effects of CXCR2 loss in regulation of tumour-infiltrating myeloid cells and their relationship to lymphocytes during bladder tumorigenesis. METHODS: Urothelial pathogenesis and immune contexture was investigated in an OH-BBN model of invasive bladder cancer with Cxcr2 deleted in myeloid cells ( LysMCre Cxcr2 flox/flox ). CXCR2 gene alterations and expression in human muscle invasive bladder cancer were analysed in The Cancer Genome Atlas. RESULTS: Urothelial tumour pathogenesis was significantly increased upon Cxcr2 deletion compared to wildtype mice. This was associated with a suppression of myeloid cell infiltration in Cxcr2-deleted bladders shortly after the carcinogen induction. Interestingly, following a transient increase of macrophages at the outset of tumour formation, an increase in T cell infiltration was observed in Cxcr2-deleted tumours. The increased tumour burden in the Cxcr2-deleted bladder was largely independent of T cells and the status of immune suppression. The Cxcr2-deleted mouse model reflected the low CXCR2 mRNA range in human bladder cancer, which showed poor overall survival. CONCLUSIONS: In contrast to previous reports of increased CXCR2 signalling associated with disease progression and poor prognosis, CXCR2 was protective against bladder cancer during tumour initiation. This is likely due to a suppression of acute inflammation. The strategy for sensitizing checkpoint immunotherapy by CXCR2 inhibition in bladder cancer may benefit from an examination of immune suppressive status.
- 1 September 2020
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 38 (9) , 737.e1-737.e10
Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays
- 1 September 2020
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 38 (9) , 737.e1-737.e10
Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays
- Open Access
- 19 September 2018
- Published by Wiley in The Journal of Pathology
- Vol. 246 (3) , 331-343
FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation
Recent studies of muscle‐invasive bladder cancer show that FGFR3 mutations are generally found in a luminal papillary tumour subtype that is characterised by better survival than other molecular subtypes. To better understand the role of FGFR3 in invasive bladder cancer, we examined the process of tumour development induced by the tobacco carcinogen OH‐BBN in genetically engineered models that express mutationally activated FGFR3 S249C or FGFR3 K644E in the urothelium. Both occurrence and progression of OH‐BBN‐driven tumours were increased in the presence of an S249C mutation compared to wild‐type control mice. Interestingly, at an early tumour initiation stage, the acute inflammatory response in OH‐BBN‐treated bladders was suppressed in the presence of an S249C mutation. However, at later stages of tumour progression, increased inflammation was observed in S249C tumours, long after the carcinogen administration had ceased. Early‐phase neutrophil depletion using an anti‐Ly6G monoclonal antibody resulted in an increased neutrophil‐to‐lymphocyte ratio at later stages of pathogenesis, indicative of enhanced tumour pathogenesis, which supports the hypothesis that suppression of acute inflammation could play a causative role. Statistical analyses of correlation showed that while initial bladder phenotypes in morphology and inflammation were FGFR3‐dependent, increased levels of inflammation were associated with tumour progression at the later stage. This study provides a novel insight into the tumour‐promoting effect of FGFR3 mutations via regulation of inflammation at the pre‐tumour stage in the bladder. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 19 September 2018
- Published by Wiley in The Journal of Pathology
- Vol. 246 (3) , 331-343
Open AccessFGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation
Recent studies of muscle‐invasive bladder cancer show that FGFR3 mutations are generally found in a luminal papillary tumour subtype that is characterised by better survival than other molecular subtypes. To better understand the role of FGFR3 in invasive bladder cancer, we examined the process of tumour development induced by the tobacco carcinogen OH‐BBN in genetically engineered models that express mutationally activated FGFR3 S249C or FGFR3 K644E in the urothelium. Both occurrence and progression of OH‐BBN‐driven tumours were increased in the presence of an S249C mutation compared to wild‐type control mice. Interestingly, at an early tumour initiation stage, the acute inflammatory response in OH‐BBN‐treated bladders was suppressed in the presence of an S249C mutation. However, at later stages of tumour progression, increased inflammation was observed in S249C tumours, long after the carcinogen administration had ceased. Early‐phase neutrophil depletion using an anti‐Ly6G monoclonal antibody resulted in an increased neutrophil‐to‐lymphocyte ratio at later stages of pathogenesis, indicative of enhanced tumour pathogenesis, which supports the hypothesis that suppression of acute inflammation could play a causative role. Statistical analyses of correlation showed that while initial bladder phenotypes in morphology and inflammation were FGFR3‐dependent, increased levels of inflammation were associated with tumour progression at the later stage. This study provides a novel insight into the tumour‐promoting effect of FGFR3 mutations via regulation of inflammation at the pre‐tumour stage in the bladder. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 12 February 2014
- Published by Wiley in The Journal of Pathology
- Vol. 233 (2) , 148-158
Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice
Although somatic mutations and overexpression of the tyrosine kinase fibroblast growth factor receptor 3 (FGFR3) are strongly associated with bladder cancer, evidence for their functional involvement in the pathogenesis remains elusive. Previously we showed that activation of Fgfr3 alone is not sufficient to initiate urothelial tumourigenesis in mice. Here we hypothesize that cooperating mutations are required for Fgfr3‐dependent tumourigenesis in the urothelium and analyse a mouse model in which an inhibitor of Pi3k–Akt signalling, Pten, is deleted in concert with Fgfr3 activation (UroIICreFgfr3+/K644EPtenflox/flox). Two main phenotypical characteristics were observed in the urothelium: increased urothelial thickness and abnormal cellular histopathology, including vacuolization, condensed cellular appearance, enlargement of cells and nuclei, and loss of polarity. These changes were not observed when either mutation was present individually. Expression patterns of known urothelial proteins indicated the abnormal cellular differentiation. Furthermore, quantitative analysis showed that Fgfr3 and Pten mutations cooperatively caused cellular enlargement, while Pten contributed to increased cell proliferation. Finally, FGFR3 overexpression was analysed along the level of phosphorylated mTOR in 66 T1 urothelial tumours in tissue microarray, which supported the occurrence of functional association of these two signalling pathways in urothelial pathogenesis. Taken together, this study provides evidence supporting a functional role of FGFR3 in the process of pathogenesis in urothelial neoplasms. Given the wide availability of inhibitors specific to FGF signalling pathways, our model may open the avenue for FGFR3‐targeted translation in urothelial disease. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 12 February 2014
- Published by Wiley in The Journal of Pathology
- Vol. 233 (2) , 148-158
Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice
Although somatic mutations and overexpression of the tyrosine kinase fibroblast growth factor receptor 3 (FGFR3) are strongly associated with bladder cancer, evidence for their functional involvement in the pathogenesis remains elusive. Previously we showed that activation of Fgfr3 alone is not sufficient to initiate urothelial tumourigenesis in mice. Here we hypothesize that cooperating mutations are required for Fgfr3‐dependent tumourigenesis in the urothelium and analyse a mouse model in which an inhibitor of Pi3k–Akt signalling, Pten, is deleted in concert with Fgfr3 activation (UroIICreFgfr3+/K644EPtenflox/flox). Two main phenotypical characteristics were observed in the urothelium: increased urothelial thickness and abnormal cellular histopathology, including vacuolization, condensed cellular appearance, enlargement of cells and nuclei, and loss of polarity. These changes were not observed when either mutation was present individually. Expression patterns of known urothelial proteins indicated the abnormal cellular differentiation. Furthermore, quantitative analysis showed that Fgfr3 and Pten mutations cooperatively caused cellular enlargement, while Pten contributed to increased cell proliferation. Finally, FGFR3 overexpression was analysed along the level of phosphorylated mTOR in 66 T1 urothelial tumours in tissue microarray, which supported the occurrence of functional association of these two signalling pathways in urothelial pathogenesis. Taken together, this study provides evidence supporting a functional role of FGFR3 in the process of pathogenesis in urothelial neoplasms. Given the wide availability of inhibitors specific to FGF signalling pathways, our model may open the avenue for FGFR3‐targeted translation in urothelial disease. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.